Ganglioside as a drug for psoriasis

• Project/Area Number: 17K10255
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Dermatology
• Research Institution: Teikyo University
• Principal Investigator: Tada Yayoi 帝京大学, 医学部, 主任教授 (00334409)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Project Status: Completed (Fiscal Year 2019)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2017: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: 乾癬 / 免疫学

Outline of Final Research Achievements

Psoriasis is a disease of Th1 and Th17 immune response. Here, we investigated the role of ganglioside of suppressing the immune response of psoriasis. IMQ applied mice was used as a psoriasis mouse model. Ganglioside GM1,GM2,GD1a,GD3,GT1b decreased the skin erythema, epidermal thickness, scale of these mice, and histopathology showed that ganglioside decreased the infiltrating T cells. Cytokine and chemokine expression of the skin , such as TNF,CXCL1/2, IL-17A, IL-22, IL-12p40, IL-23p19, CCL20 and anti microbial peptide DEFB4 expression was decreased by mRNA level. Therefore, our result suggested that IMQ suppressed and improved psoriasis like inflammation of psoriasis mice model.

Academic Significance and Societal Importance of the Research Achievements

乾癬は慢性の炎症生皮膚疾患であるが、マウスの乾癬モデルを用いた我々の研究はガングリオシドがその治療薬として用いられる可能性を示すことができた。

Research Products

• [Journal Article] Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis. (2019)
  • Author(s): Shimizu T, Tada Y et al.
  • Journal Title: J Dermatol Sci Volume: 95 Issue: 3 Pages: 90-98
  • DOI: 10.1016/j.jdermsci.2019.07.006
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Patient preference for biologic treatments of psoriasis in Japan. (2019)
  • Author(s): Tada Y, Ishii K, Kimura J, Hanada K, Kawaguchi I.
  • Journal Title: J Dermatol. Volume: 印刷中 Issue: 6 Pages: 466-477
  • DOI: 10.1111/1346-8138.14870
  • Peer Reviewed
• [Journal Article] Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation. (2019)
  • Author(s): Komatsuda S, Kamata M, Chijiwa C, Namiki K, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Abe K, Yamamoto T, Aozasa N, Sugiura K, Tada Y.
  • Journal Title: J Dermatol. Volume: 46 Issue: 1 Pages: 73-75
  • DOI: 10.1111/1346-8138.14711
  • Peer Reviewed
• [Journal Article] The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production. (2018)
  • Author(s): Hau CS, Shimizu T, Tada Y, Kamata M, Takeoka S, Shibata S, Mitsui A, Asano Y, Sugaya M, Kadono T, Sato S, Watanabe S.
  • Journal Title: J Dermatol Sci. Volume: 92 Issue: 2 Pages: 117-126
  • DOI: 10.1016/j.jdermsci.2018.08.007
  • Peer Reviewed
• [Journal Article] Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy (2018)
  • Author(s): Imafuku S, Zheng M, Tada Y, Zhang X, Theng C, Thevarajah S, Zhao Y, Song HJ.
  • Journal Title: J Dermatol. Volume: 45 Issue: 7 Pages: 805
  • DOI: 10.1111/1346-8138.14338
  • URL: https://localhost/en/publications/fd6e8e12-5390-4373-a7b4-a4e147b9ac8c
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. (2017)
  • Author(s): Ohtsuki M, Morita A, Igarashi A, Imafuku S, Tada Y, Fujita H, Fujishige A, Yamaguchi M, Teshima R, Tani Y, Nakagawa H.
  • Journal Title: J Dermatol. Volume: 44 Issue: 10 Pages: 1105-1111
  • DOI: 10.1111/1346-8138.13911
  • Peer Reviewed
• [Journal Article] Serum angiopoietin-2 level as a potential biomarker in psoriasis vulgaris (2017)
  • Author(s): Takahashi T, Asano Y, Shibata S, Tada Y, Sato S.
  • Journal Title: J Dermatol. Volume: 44 Issue: 2 Pages: 205
  • DOI: 10.1111/1346-8138.13529
  • URL: https://localhost/en/publications/2ef31cab-c537-404e-8db0-326275547451
  • Peer Reviewed